Vandria is a biopharmaceutical company that develops best-in-class small molecule mitophagy inducers to treat age-related and chronic diseases in the fields of Muscle- and CNS diseases with large unmet medical need.
Vandria has raised €28M across 1 funding round from 3 investors, most recently a Series A round in Aug 2024. Based in Lausanne, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-08-21 | Series A | €28M |
| Dolby Family Ventures,Hevolution Foundation,ND Capital |
| View deal → |
